A Phase 2 Study to Evaluate the Safety and Efficacy of CKD-498 in Female Patients With Androgenetic Alopecia
A Phase 2, Randomized, Double-blind, Multi-center, Parallel-group Trial to Evaluate the Efficacy and Safety of CKD-498 in Female Patients With Androgenetic Alopecia
In the register
The register attaches this trial to CKD-498 (Chong Kun Dang Pharmaceutical), currently at “Phase 2” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Completed
- Declared phase
- Phase 2
- Sponsor
- Chong Kun Dang Pharmaceutical
- Participants (registry)
- 121
- Start
- December 2022
- Primary completion
- December 2023
- Study completion
- December 2023
- Last registry update
- June 2024
- Countries
- South Korea
Conditions studied: Androgenetic Alopecia
Interventions: CKD-498 dose#1, CKD-498 dose#2, CKD-498 dose#3, Placebo of CKD-498 dose#1, Placebo of CKD-498 dose#2, Placebo of CKD-498 dose#3
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.